Status:
COMPLETED
Metoclopramide as Treatment of Clozapine-induced Hypersalivation
Lead Sponsor:
Beersheva Mental Health Center
Collaborating Sponsors:
Tirat Carmel Mental Health Center
Conditions:
Clozapine-induced Hypersalivation
Eligibility:
All Genders
19-57 years
Phase:
PHASE3
Brief Summary
Hypersalivation (sialorrhea or ptyalism) is known as a frequent, disturbing, uncomfortable adverse effect of clozapine therapy that can lead to noncompliance. Until now there is no effective enough tr...
Detailed Description
Hypersalivation (sialorrhea or ptyalism) is known as a frequent, disturbing, uncomfortable adverse effect of clozapine therapy that may persist for several years. This side effect is usually dose-rela...
Eligibility Criteria
Inclusion
- Age 18-60 years, male or female
- DSM-IV criteria for schizophrenia
- Clozapine treatment
- At least score \>2 on the Nocturnal Hypersalivation Rating Scale (NHRS)
Exclusion
- Evidence of organic brain damage, mental retardation, alcohol or drug abuse
- Patients suffering from pheochromocytoma
- Patients suffering from Parkinson's disease
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
61 Patients enrolled
Trial Details
Trial ID
NCT02222220
Start Date
January 1 2012
End Date
May 1 2014
Last Update
August 21 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Be'er Sheva Mental Health Center,
Beersheba, Israel, 8417000